Johny Alencherry, MD
Internal Medicine · Martinsburg, WVNPI 1952387300
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,450 of the $27,310 with a category attached, or 71.2%. AstraZeneca accounts for 80.3% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2021 at $17,433 and has fallen 97.5% since, to $440 in 2025. Among internal medicine clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 470 payments — averaging $58.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$22K
- GSK$1K
- Boehringer Ingelheim$974
- Mylan Specialty L.p.$435
- Grifols USA, LLC$358
- Actelion Pharmaceuticals US, Inc.$306
- plus $2K from 33 others
What the payments were for
- Speaking & faculty fees$19,45071%
- Travel & lodging$1280%
- Food & beverage$7,67628%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 115 | $21,927 |
| GSK | 107 | $1,211 |
| Boehringer Ingelheim | 73 | $974 |
| Mylan Specialty L.p. | 23 | $435 |
| Grifols USA, LLC | 26 | $358 |
| Actelion Pharmaceuticals US, Inc. | 10 | $306 |
| Regeneron Healthcare Solutions, Inc. | 13 | $263 |
| Jazz Pharmaceuticals Inc. | 5 | $208 |
| Sunovion Pharmaceuticals Inc. | 13 | $193 |
| Pfizer | 12 | $174 |
| Novo Nordisk | 10 | $146 |
| Genentech USA, Inc. | 6 | $96 |
| United Therapeutics Corporation | 4 | $91 |
| Teva Pharmaceuticals USA, Inc. | 5 | $83 |
| Lilly USA, LLC | 4 | $82 |
| Harmony Biosciences LLC | 5 | $78 |
| Exact Sciences | 3 | $61 |
| Advanced Respiratory, Inc | 2 | $58 |
| Insmed, Inc. | 3 | $47 |
| Novartis | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Electromed, Inc. | 4 | $38 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Sanofi | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Philips North America LLC | 2 | $33 |
| Resmed Corp | 2 | $30 |
| Bayer | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Circassia Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| Fisher & Paykel Healthcare Inc | 1 | $11 |
| Biomerieux Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,310 in reported general payments places this provider in the 95th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 312 | $226,697 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 101 | $61,157 |
| Dupixent PenDupilumab | 11 | $48,696 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $19,143 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $17,813 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $15,636 |
| Arnuity ElliptaFluticasone Furoate | 27 | $7,341 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,874 |
| Montelukast Sodium | 201 | $2,150 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $2,043 |
| Theophylline ErTheophylline Anhydrous | 60 | $1,247 |
| Levocetirizine Dihydrochloride | 87 | $1,180 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,107 |
| Azelastine Hcl | 12 | $371 |
| Bupropion Hcl SrBupropion Hcl | 33 | $349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,211 | $286,630445 claims |
| AstraZenecaBreztri Aerosphere | $21,927 | $61,157101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Martinsburg
- Samuel MorrisMartinsburg$9K
- William ChapmanCharleston$1.7M
- David PickeringParkersburg$599K
- Govind PatelFairmont$59K
- Bisher MustafaHuntington$28K
- Ali KhanBuckhannon$21K
- Joseph HashemBerkeley Springs$21K
- David PatickHuntington$18K
- Phillip TriplettCharleston$17K
- Atul ShettyWeirton$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.